RESEARCHER PROFILE
Georgina Hughes,
Pharmacist & PhD Candidate
University of South Australia Clinical and Health Sciences
Registry of Senior Australians (ROSA)
South Australian Health and Medical Research Institute
Georgina Hughes is a pharmacist & PhD Candidate with the University of South Australia Clinical and Health Sciences and the Registry of Senior Australians (ROSA), undertaking research at South Australian Health and Medical Research Institute (SAHMRI).
Georgina’s PhD study and first published paper was on how to improve the safe and effective use of antidepressant medicines and optimise quality use of medicines in older people accessing residential aged care.
The study, published in the Journal of American Medical Directors Association (JAMDA), was led by Georgina, in collaboration with Professor Maria Inacio and Associate Professor Janet Sluggett. It’s Australia’s first national study investigating the use of antidepressants among older people living in residential aged care homes across the country, analysing the de-identified data of 779,659 residents from 3,371 aged care homes, between 2006 and 2019.
“We found antidepressants were used by 46.1% of residents in 2006 and this increased to 58.5% of residents in 2019,” Ms Hughes said.
“Nearly six in every ten residents of aged care homes are using an antidepressant, which is much higher than use in the general older population.”
The use of antidepressant medicines among older people in aged care homes in Australia is high, and there is a need for better mental health support and safer use of antidepressants to improve clinical care and health outcomes for older people.
Antidepressant medicines can have side effects, especially in older people, and Australia is one of the largest consumers globally.
Almost 60% of aged care home residents are using antidepressant medicines, prompting the need to investigate the reasons for such high usage.
Georgina talks to how big data is crucial in understanding and improving the use of antidepressant medicines in aged care, leading to better clinical care and health outcomes for older people in Australia.
Georgina is passionate about practice-informing, translational and innovative research to improve quality use of medicines and health outcomes.
-
Touched by bowel cancer and chasing science outcomes
Dr Josephine Wright is a Senior Research Fellow in the Gut Cancer group. She has been developing a translational network of labs, hospitals and clinics to enable validation of new approaches to prevent and treat colorectal and gastric cancer. Her key focus is studying human tumour organoids to better personalise therapy in cancer.
-
World-first clinical trial improves patient outcomes for kidney transplants (2023)
A world-first clinical trial conducted at the Royal Adelaide Hospital (RAH) and at hospitals across Australia and New Zealand has identified the best fluid treatment to reduce the risk of patients requiring dialysis after a kidney transplant.
Around one in three people who receive a kidney transplant suffer delayed graft function, which means the transplant doesn’t work immediately and they require dialysis.
The lead-author of the study, was Royal Adelaide Hospital Nephrologist and University of Adelaide researcher, Dr Michael Collins.
-
CASE STUDY Next Generation Condom Contraception
Eudaemon Technologies, an early-stage medtech company with a focus on sexual reproductive health, is developing a hydrogel condom to address the need for a better feeling, next generation condom, with the potential to improve user experience and address issues with traditional latex condoms.
“Over 1 million STI’s being diagnosed every day and up to 120 million unplanned pregnancies every year result in a $60 billion health burden across the globe”, says Co-Founder and Executive Director of Operations, Dr Simon Cook.
Formed in 2018, the company focuses on developing tough hydrogels as an alternative to address issues with odour, colour, and taste commonly associated with latex condoms. This technology can be loaded with small molecule drugs for flavours or anti-STI compounds, and was developed in response to a grant from the Bill and Melinda Gates Foundation to address unplanned pregnancies and STIs.
